# Predicta Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/predicta-biosciences-2

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.predictabiosciences.com/
- Total disclosed funding: $23M
- Latest round: Series A (Oct 9, 2025)
- Investors on record: 7

## About

Predicta Biosciences, Inc., based in Cambridge, Massachusetts, develops advanced diagnostic solutions for blood cancers, primarily through its flagship product, GenoPredicta™, which utilizes whole genome sequencing for enhanced disease detection and management.Founded in 2023, Predicta Biosciences, Inc. specializes in molecular diagnostics, particularly for oncology. The company has engaged in one deal, raising a total of USD 23.4 mn in Series A funding, which occurred on October 9, 2025. The founder's background is not detailed, and there are no records of prior companies. The company operates out of Cambridge, US.Predicta Biosciences specializes in advanced diagnostic solutions, primarily through its flagship product, GenoPredicta™, which leverages whole genome sequencing (WGS) of cells obtained from both bone marrow and blood. This innovative platform provides unprecedented sensitivity and accuracy for the diagnosis of multiple myeloma and other plasma cell dyscrasias, significantly outpacing traditional methods such as fluorescence in situ hybridization (FISH). The GenoPredicta™ technology enables the detection of critical genomic alterations, including single nucleotide variants (SNVs) and small insertions/deletions (InDels), essential for understanding disease prognosis and therapeutic response. By facilitating routine blood monitoring, Predicta aims to empower healthcare providers with essential insights for timely disease intervention and management. The company primarily serves oncologists and hematologists in the United States, enhancing clinical outcomes through its innovative diagnostic capabilities.Predicta Biosciences generates revenue through its B2B model, catering to healthcare providers and institutions that require advanced diagnostic tools for blood cancers and autoimmune diseases. The company's flagship product, GenoPredicta™, is sold directly to healthcare facilities, enabling physicians to order tests that provide comprehensive genomic data for patient management. The pricing structure for GenoPredicta™ reflects its advanced technological capability and the value it brings to clinical practice, though specific pricing details are proprietary. By offering molecular diagnostic services that include minimal residual disease (MRD) detection and genomic characterization at the single-cell level, Predicta facilitates ongoing patient monitoring and therapeutic decision-making, enhancing its appeal within the oncology and hematology markets. In October 2025, Predicta Biosciences, Inc. raised USD 23.4 million in Series A funding led by new investor Engine Ventures, with participation from other new investors Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, BrightEdge Ventures, Binney Street Capital, and Myeloma Investment Fund. The company will use the October 2025 funding to developing novel diagnostic and therapeutic discovery solutions. Predicta aims to launch new products targeting additional blood cancer diagnostics and to expand its market reach, although specific geographic regions and product details have not been disclosed.

## Funding rounds

- Series A, Oct 9, 2025, $23M — Mass General Brigham Ventures, Illumina Ventures, Engine Ventures, BrightEdge Ventures, Lightchain Capital, Binney Street Capital, Myeloma Investment Fund

## Investors

- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series A
- Engine Ventures (https://capitalatlas.ai/funds/engine-ventures) — Series A
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series A
- Lightchain Capital (https://capitalatlas.ai/funds/lightchain-capital) — Series A
- Binney Street Capital (https://capitalatlas.ai/funds/binney-street-capital) — Series A
- Myeloma Investment Fund (https://capitalatlas.ai/funds/myeloma-investment-fund) — Series A